> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-70/
- Published: 2022-02-27T12:00:00.000Z
- Updated: 2026-09-14T17:34:26.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151254

**FDA Amends Animal Drug Regs for Approvals**  
2/25/2022 *Federal Register* notice: FDA is amending the animal drug regulations to reflect application-related actions for NADAs, ANADAs and conditionally approved NADAs made during 7/2021, 8/2021 and 9/2021\. Additionally, the agency is informing the public about the availability of summaries of the basis of approval and of environmental review documents, where applicable. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-03538.pdf?ref=fdaweb.com).

**FDA Withdrawing 5 No-Longer-Marketed ANDAs**  
2/25/2022 *Federal Register* notice: FDA is withdrawing approval of five ANDAs from multiple applicants after they notified the agency that the drug products are no longer marketed and requested their withdrawal. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-04153.pdf?ref=fdaweb.com).

**Proposal to Harmonize Device QSR with ISO 13485**  
2/24/2022 *Federal Register* notice: FDA is publishing a proposed rule to amend medical device current GMP requirements of the Quality System Regulation to align more closely with the International Organization for Standardization’s 13485\. It is also proposing additional requirements to clarify device GMP requirements for combination products. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-02-23/pdf/2022-03227.pdf?ref=fdaweb.com).

**Meeting on Biosimilar User Fee Program Assessment**  
2/23/2022 *Federal Register* notice: FDA is announcing a 3/22 virtual public meeting entitled “Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (BsUFA),” and an opportunity for public comment. The topics to be discussed are the final assessment and public stakeholder views about the program. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-03926.pdf?ref=fdaweb.com).